Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
argenx NV ADR(ARGX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARGX
09/25/2026: ARGX (4-star) is a SELL. SELL for 3 days. Simulated Profits (-4.75%). Updated daily EoD!
argenx is a growing biotechnology company that specializes in developing innovative antibody-based therapies for autoimmune diseases. Its primary asset, VYVGART, has established a firm position in treating generalized myasthenia gravis and CIDP, serving as the main driver of its current revenue growth. The company's investment story centers on its potential to expand this drug into new indications while leveraging its proprietary discovery platform. Key risks include significant competition within the immunology space, the challenges of maintaining rapid commercial growth, and high operational costs. The stock may best suit growth-oriented investors who are comfortable with the inherent volatility of the biotechnology sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers significant top-line growth potential through the expansion of its lead asset, VYVGART. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts positively to clinical trial results and new regulatory approvals. |
| Value investor | Weak fit | The stock trades at a premium based on future growth expectations rather than current earnings or book value. |
| Dividend investor | Weak fit | argenx does not pay a dividend and is not suitable for income-seeking investors. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile and subject to binary outcomes from clinical results. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's value is highly sensitive to clinical trial data and regulatory news. |
| Valuation risk | Medium / high | Current valuations rely heavily on long-term growth and successful label expansion. |
| Competition risk (FcRn inhibitors) | Medium / high | Multiple competitors are developing similar drugs which could erode market share. |
| Business quality | Medium | While the platform is innovative, the company is still maturing its commercial operations. |
| Dividend income | Low / none | Investors should not expect any income from this holding. |
| Execution risk | Medium | Scaling commercial distribution and maintaining high growth rates is challenging. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 52.16% | Avg. Invested days 58 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 59.84B USD | Price to earnings Ratio 36.61 | 1Y Target Price 1180.61 |
Price to earnings Ratio 36.61 | 1Y Target Price 1180.61 | ||
Volume (30-day avg) 274.1K shares | Beta -0.03 | 52 Weeks Range 661.85 - 1072.75 | Updated Date 09/25/2026 |
52 Weeks Range 661.85 - 1072.75 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 26.28 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Global net sales of VYVGART for various autoimmune indications. | The vast majority of the company's money comes from selling its single approved drug, VYVGART. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 36.61 | Forward PE 25.91 | Enterprise Value 54.72B | Price to Sales(TTM) 11.32 |
Enterprise Value 54.72B | Price to Sales(TTM) 11.32 | ||
Enterprise Value to Revenue 10.47 | Enterprise Value to EBITDA 30.68 | Shares Outstanding 62.19M | Shares Floating 1.56B |
Shares Outstanding 62.19M | Shares Floating 1.56B | ||
Percent Insiders - | Percent Institutions 46.08 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About argenx NV ADR
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2017-05-18 | CEO & Executive Director Ms. Karen Massey | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1863 | Website https://argenx.com |
Full time employees 1863 | Website https://argenx.com | ||
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.